Amylyx’s experimental oral treatment AMX0035 safely and effectively slows functional decline in amyotrophic lateral sclerosis (ALS) patients with rapidly progressing disease, according to full data from the CENTAUR Phase 2/3 trial.

Only changes in upper limb strength were significantly different from those seen in placebo-treated patients, the data show. Meanwhile, AMX0035 was associated with a trend toward slower rates of decline in muscle strength and lung function, as well as fewer hospitalizations.- https://alsnewstoday.com/2020/09/03/...aign=OneSignal